非小细胞肺癌免疫治疗的研究进展

Advances in Immunotherapy of Non-small Cell Lung Cancer

非小细胞肺癌(NSCLC)是具有高发病率和病死率的恶性肿瘤。尽管化疗和分子靶向治疗不断优化,但晚期NSCLC患者的5年生存率仍较低。目前,免疫检查点抑制剂治疗在抗肿瘤领域中取得了重大突破,特别是程序性死亡受体-1/程序性死亡配体-1抑制剂治疗被认为是NSCLC治疗的主要手段。本文就NSCLC的免疫治疗研究现状及相关问题进行综述。

Non-small cell lung cancer(NSCLC)is one of the malignancies with high morbidity and mortality.Despite the continuous optimization of chemotherapy and molecularly targeted therapies,the 5-year survival rate for patients with advanced NSCLC remains low.Currently,immune checkpoint inhibitor therapy has made a major breakthrough in the anti-tumor field,especially programmed death receptor-1/programmed death ligand-1 inhibitor therapy,which is considered to be the mainstay of treatment for NSCLC.This article reviews the current research status and related issues of immunotherapy for NSCLC.